大分割胸壁放疗安全有效:一项前瞻性II期试验的初步结果
这项前瞻性II期试验评估了11次大分割胸壁放疗(含瘤床加量共15次)在II–IIIA期乳腺癌术后的安全性和有效性。中位随访32个月,未观察到3级毒性,2级皮肤毒性最常见(24%),3年局部无复发生存率为89.2%。作者据此设计了一项常规分割对比大分割的III期随机试验。
要点
- 11次大分割胸壁放疗(含瘤床加量共15次)未观察到3级毒性,2级皮肤毒性最常见(16/67,24%)。
- 2例孤立同侧胸壁复发(2/67,粗率3%),3年估计局部无复发生存率89.2%(95%CI 0.748–0.956)。
- 38例重建患者中植入物丢失或失败率24%(9/38),非计划手术矫正率8%(3/38),总并发症率32%。
核心结论
- 该II期前瞻性研究提供了目前报告的最短疗程胸壁放疗之一,胸壁和淋巴结照射11次、含加量共15次,显示低毒性和高局部控制。
- 作者据此设计了一项常规分割对比大分割胸壁放疗的III期前瞻性随机试验,即将启动。
研究设计与样本
- 前瞻性II期试验,入组69例II–IIIA期乳腺癌女性,其中67例可分析。
- 胸壁和引流区域淋巴结放疗剂量36.63 Gy,11次,每次3.33 Gy,共11天;随后可选瘤床加量4次,每次3.33 Gy。
- 主要终点为无任何3级或以上毒性,并依据预设毒性阈值设置早期停止标准。
主要发现
- 中位随访32个月,未观察到3级毒性。
- 报告29例次2级毒性,2级皮肤毒性最常见(16/67,24%)。
- 2例孤立同侧胸壁肿瘤复发(2/67,粗率3%)。
- 3年估计局部无复发生存率89.2%(95%CI 0.748–0.956),3年估计远处无复发生存率90.3%(95%CI 0.797–0.956)。
- 41例患者行胸壁重建;3例在放疗前因感染取出扩张器;38例中植入物丢失或失败率24%(9/38),非计划手术矫正率8%(3/38),总并发症率32%。
关键数值与推荐
- 胸壁和引流区域淋巴结放疗36.63 Gy,11次,每次3.33 Gy,共11天。
- 瘤床加量可选,4次,每次3.33 Gy。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Conventionally fractionated postmastectomy radiation therapy (PMRT) takes approximately 5 to 6 weeks. Data supporting hypofractionated PMRT is limited. We prospectively evaluated a short course of hypofractionated PMRT, in which therapy was completed in 15 treatment days. Patients and Methods We delivered PMRT at a dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11 days to the chest wall and the draining regional lymph nodes, followed by an optional mastectomy scar boost of four fractions of 3.33 Gy. Our primary end point was freedom from any grade 3 or higher toxicities. We incorporated early stopping criteria on the basis of predefined toxicity thresholds. Results We enrolled 69 women with stage II to IIIa breast cancer, of whom 67 were eligible for analysis. After a median follow-up of 32 months, there were no grade 3 toxicities. There were 29 reported grade 2 toxicities, with grade 2 skin toxicities being the most frequent (16 of 67; 24%). There were two patients with isolated ipsilateral chest wall tumor recurrences (2 of 67; crude rate, 3%). Three-year estimated local recurrence-free survival was 89.2% (95% CI, 0.748 to 0.956). The 3-year estimated distant recurrence-free survival was 90.3% (95% CI, 0.797 to 0.956). Forty-one patients had chest wall reconstructions; three had expanders removed for infection before radiation therapy. The total rate of implant loss or failure was 24% (9 of 38), and the unplanned surgical correction rate was 8% (3 of 38), for a total complication rate of 32%. Conclusion To our knowledge, our phase II prospective study offers one of the shortest courses of PMRT reported, delivered in 11 fractions to the chest wall and nodes and 15 fractions inclusive of a boost. We demonstrated low toxicity and high local control with this schedule. On the basis of our data, we have designed a cooperative group phase III prospective, randomized trial of conventional versus hypofractionated PMRT that will activate soon.
引用
- Khan AJ, Poppe MM, Goyal S, et al. Hypofractionated Postmastectomy Radiation Therapy Is Safe and Effective: First Results From a Prospective Phase II Trial. J Clin Oncol. 2017. PMID: 28459606. doi:10.1200/JCO.2016.70.7158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。